Sonic Healthcare – Buy Signal

SHL has strengthened its German footprint with the purchase of two laboratories from Medical Laboratory Bremen for A$90 million.

The deal is EPS accretive in the first year with margin expansion & synergy gains achievable in the near term.  We expect Sonic to deliver 7 – 9% EPS growth in FY17 and FY18.

You’re not a member!  Trial today

FY17 revenue $5.2b, on EBIT  of $920m, Net Profit $$480m, EPS of $1.20 & DPS $0.78, places the stock on a forward yield of 3.6%.

We like Sonic as a core portfolio position, however the low yield and moderate EPS growth encourages the use of a covered call to enhance the cash flow and boost the overall investment return.

Chart – Sonic Healthcare

 

 

Ready to elevate your investing?

Join Investor Signals today and start your journey to better, more disciplined returns.